

## Company Overview

Navidea Biopharmaceuticals, Inc. (NYSE MKT: NAVB) is a leader in precision medicine with immuno-targeted products designed to help identify the sites and pathways of undetected disease and enable better diagnostic accuracy, clinical decision-making, targeted treatment and, ultimately, patient care. Applying our Manocept™ technology, Navidea seeks to develop next-generation targeted diagnostics and therapies for cancer, autoimmune conditions, and other inflammatory diseases. The company, founded in 1983, maintains headquarters in Dublin, Ohio.

## Navidea Biopharmaceuticals Announces Acceptance of Abstract for Presentation at the American College of Rheumatology Annual Meeting

Oct 9 2020, 7:30 AM EDT

## Navidea Biopharmaceuticals to Ring Opening Bell at the New York Stock Exchange

Sep 28 2020, 7:30 AM EDT

## Navidea Biopharmaceuticals to Present at H.C. Wainwright 22nd Annual Global Investment Conference

Sep 8 2020, 4:05 PM EDT

## Stock Overview

**Symbol** NAVB  
**Exchange** NYSE American  
**Market Cap** 67.9m  
**Last Price** \$2.58  
**52-Week** \$0.63 - \$5.3569

10/19/2020 03:59 PM EDT

## Investor Relations

Jed Latkin  
Chief Executive Officer, CFO and  
COO  
T: 614-973-7490  
[jlatkin@navidea.com](mailto:jlatkin@navidea.com)

## Management Team

### Jed A. Latkin

Chief Executive Officer, Chief Financial Officer and Chief Operating Officer

### William Regan

Chief Compliance Officer

### Michael Rosol, Ph.D.

Chief Medical Officer

## Navidea Biopharmaceuticals, Inc.

4995 Bradenton Avenue  
Suite 240  
Dublin, OH 43017

## Disclaimer

Except for the historical information contained here in, the matters discussed in this document are forward-looking statements that involve risks and uncertainties, including but not limited to business conditions and the amount of growth in our industry and general economy, competitive factors, and other risks detailed from time to time in the Company's SEC reports, including but not limited to its annual reports on form 10-K and its quarterly reports on Form 10-Q. The company does not undertake any obligation to update forward-looking statements. All trademarks and brand name are the property of their respective companies.